Build a Better Process
Build a Better Process
/ factorpad.com / stocks / f68zkc.html
An ad-free and cookie-free website.
Our quantitative data points are meant to provide a high-level understanding of factors in equity risk models for Atara Biotherapeutics Inc. Portfolio managers use these models to forecast risk, optimize portfolios and review performance.
We show how ATRA stock compares to 2,000+ US-based stocks, and to peers in the Manufacturing sector and Biological Product (except Diagnostic) Manufacturing industry.
Please do not consider this data as investment advice. Data is downloaded from sources we deem reliable, but errors may occur.
Atara Biotherapeutics, Inc.(@Atarabio) is a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune disease. With its lead program in Phase 3 clinical development, Atara is the most advanced allogeneic T-cell immunotherapy company and intends to rapidly deliver off-the-shelf treatments to patients with high unmet medical need. Its platform leverages the unique biology of EBV T cells and has the capability to treat a wide range of EBV-associated diseases, or other serious diseases through incorporation of engineered CARs (chimeric antigen receptors) or TCRs (T-cell receptors). Atara is applying this one platform to create a robust pipeline including: tab-cel® in Phase 3 development for Epstein-Barr virus-driven post-transplant lymphoproliferative disease (EBV+ PTLD) and other EBV-driven diseases; ATA188, a T-cell immunotherapy targeting EBV antigens as a potential treatment for multiple sclerosis; and multiple next-generation chimeric antigen receptor T-cell (CAR-T) immunotherapies for both solid tumors and hematologic malignancies. Improving patients' lives is its mission and it will never stop working to bring transformative therapies to those in need. Atara is headquartered in South San Francisco and its leading-edge research, development and manufacturing facility is based in Thousand Oaks, California.
Many of the following risk metrics are standardized and transformed into quantitative factors in institutional-level risk models.
Rankings below represent percentiles from 1 to 100, with 1 being the lowest rating of risk.
Stocks with higher beta exhibit higher sensitivity to the ups and downs in the market. (↑↑)
Stocks with higher market capitalization often have lower risk. (↑↓)
Higher average daily dollar volume over the past 30 days implies lower liquidity risk. (↑↓)
Higher price momentum stocks, aka recent winners, equate to lower risk for many investors. (↑↓)
Style risk factors often include measures of profitability and payout levels.
Companies with higher earnings generally provide lower risk. (↑↓)
Companies with higher dividend yields, if sustaintable, are perceived to have lower risk. (↑↓)
/ factorpad.com / stocks / f68zkc.html
A newly-updated free resource. Connect and refer a friend today.
by